Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
AssigneeMedical College of Georgia Research Institute, Inc.
InventorsDavid Munn, Andrew Mellor
Life of this patent
Estimating the term…
Abstract
The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.
Claims17
A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition consisting essentially of 1-methyl-D-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.
A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition comprising 1-methyl-D-tryptophan, but not 1-methyl-L-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.
A method of reducing tumor size or slowing tumor growth in a subject, the method comprising administering to the subject a pharmaceutical composition consisting essentially of 1-methyl-D-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.
A method of reducing tumor size or slowing tumor growth in a subject, the method comprising administering to the subject a pharmaceutical composition comprising 1-methyl-D-tryptophan, but not 1-methyl-L-tryptophan, wherein the pharmaceutical composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.
Dependencies are inferred from the claim text.